The prognostic significance of residual disease, measured by flow cytometry or PCR-based assays, has been established in patients with acute myeloid leukaemia (AML). The results of a recent study involving almost 500 patients in morphological remission demonstrate that detection of persistent mutations using next-generation sequencing provides information complementary to that obtained using the established methods and offer insights into AML evolution.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia
Current Medical Science Open Access 28 June 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hourigan, C. S. et al. Measurable residual disease testing in acute myeloid leukaemia. Leukemia 31, 1482–1490 (2017).
Döhner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136–1152 (2015).
Döhner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424–447 (2017).
Klco, J. M. et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 314, 811–822 (2015).
Getta, B. M. et al. Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol. Blood Marrow Transplant. 23, 1064–1071 (2017).
Jongen-Lavrencic, M. et al. Molecular minimal residual disease in acute myeloid leukemia. N. Engl. J. Med. 378, 1189–1199 (2018).
Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16 (2015).
Kayser, S. et al. Minimal residual disease-directed therapy in acute myeloid leukemia. Blood 125, 2331–2335 (2015).
Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat. Rev. Genet. 19, 269–285 (2018).
Acknowledgements
R.B.W. acknowledges funding support from the Leukemia & Lymphoma Society as a Scholar in Clinical Research. F.R.A. acknowledges funding support from the US NIH (grants P01 CA18029 and P30 CA15704).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Walter, R.B., Appelbaum, F.R. Next-generation sequencing for measuring minimal residual disease in AML. Nat Rev Clin Oncol 15, 473–474 (2018). https://doi.org/10.1038/s41571-018-0040-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0040-0
This article is cited by
-
Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia
Nature Cancer (2021)
-
Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia
Current Medical Science (2021)
-
Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry
Current Hematologic Malignancy Reports (2018)
